MACE | MACE-plus | CVD-related death | ||||
---|---|---|---|---|---|---|
Validation | ||||||
C-statistic, training set | 0.70 | 0.72 | 0.78 | |||
C-statistic, validation set | 0.70 | 0.72 | 0.77 |
Predictors | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value |
---|---|---|---|---|---|---|
Age group (reference: 50–54 years old) | ||||||
55–59 years old | 1.08 (0.86, 1.36) | 0.513 | 1.01 (0.85, 1.21) | 0.883 | 1.33 (0.84, 2.11) | 0.230 |
60–64 years old | 1.24 (1.00, 1.54) | 0.049* | 1.12 (0.95, 1.33) | 0.168 | 1.72 (1.11, 2.66) | 0.014* |
65–69 years old | 1.35 (1.10, 1.67) | 0.005* | 1.20 (1.01, 1.41) | 0.033* | 2.15 (1.41, 3.28) | < 0.001* |
70–74 years old | 1.52 (1.24, 1.88) | < 0.001* | 1.30 (1.11, 1.54) | 0.001* | 2.67 (1.76, 4.06) | < 0.001* |
75–79 years old | 1.72 (1.40, 2.12) | < 0.001* | 1.43 (1.21, 1.68) | < 0.001* | 3.13 (2.06, 4.75) | < 0.001* |
80–84 years old | 2.20 (1.79, 2.70) | < 0.001* | 1.82 (1.55, 2.14) | < 0.001* | 4.60 (3.04, 6.97) | < 0.001* |
85 and above | 2.23 (1.79, 2.77) | < 0.001* | 1.81 (1.52, 2.15) | < 0.001* | 4.82 (3.14, 7.39) | < 0.001* |
Race (reference: Caucasian) | ||||||
African American | 0.81 (0.70, 0.93) | 0.003* | ||||
Asian | 0.58 (0.37, 0.92) | 0.021* | ||||
Other/unknown | 1.04 (0.93, 1.17) | 0.474 | ||||
Ethnicity (reference: non-Hispanic) | ||||||
Hispanic | 0.98 (0.82, 1.17) | 0.830 | 0.92 (0.79, 1.08) | 0.315 | 0.69 (0.51, 0.93) | 0.016* |
Unknown | 1.16 (1.10, 1.24) | < 0.001* | 1.14 (1.09, 1.20) | < 0.001* | 1.14 (1.03, 1.27) | 0.013* |
End of baseline period prior to 2011a | 1.43 (1.34, 1.53) | < 0.001* | 1.39 (1.32, 1.48) | < 0.001* | 1.83 (1.67, 2.01) | < 0.001* |
Geographic region (reference: South) | ||||||
Midwest | 0.83 (0.75, 0.91) | < 0.001* | ||||
Northeast | 0.73 (0.63, 0.83) | < 0.001* | ||||
West | 0.84 (0.73, 0.97) | 0.014* | ||||
Other/unknown | 1.07 (0.85, 1.33) | 0.570 | ||||
Insurance type (reference: health maintenance organization [HMO]) | ||||||
Point-of-service (POS) | 1.11 (0.97, 1.27) | 0.142 | 0.79 (0.60, 1.05) | 0.105 | ||
Preferred provider organization (PPO) | 1.21 (1.08, 1.34) | < 0.001* | 0.84 (0.69, 1.03) | 0.092 | ||
Exclusive provider organization (EPO) | 1.08 (0.86, 1.36) | 0.483 | 0.58 (0.34, 0.98) | 0.043* | ||
Indemnity (IND) | 1.29 (1.07, 1.55) | 0.007* | 1.23 (0.91, 1.66) | 0.183 | ||
Other | 1.01 (0.96, 1.07) | 0.631 | 0.89 (0.81, 0.98) | 0.018* | ||
Payer type | ||||||
Commercial | 0.81 (0.75, 0.89) | < 0.001* | 0.77 (0.68, 0.87) | < 0.001* | 0.84 (0.67, 1.06) | 0.135 |
Prior CVD diagnoses (ref: no diagnosis) | ||||||
Myocardial infarction | 1.24 (1.16, 1.33) | < 0.001* | 1.13 (1.07, 1.20) | < 0.001* | ||
Stroke | 1.34 (1.26, 1.43) | < 0.001* | 1.13 (1.06, 1.19) | < 0.001* | ||
Congestive heart failure | 1.39 (1.30, 1.49) | < 0.001* | 1.91 (1.80, 2.03) | < 0.001* | 1.97 (1.78, 2.18) | < 0.001* |
Time from last observed CVD diagnosis to end of baseline period, months (reference: less than 1 month) | ||||||
1–3 months | 0.80 (0.73, 0.87) | < 0.001* | 0.76 (0.70, 0.82) | < 0.001* | 0.83 (0.74, 0.93) | 0.002* |
3–6 months | 0.66 (0.60, 0.73) | < 0.001* | 0.62 (0.57, 0.67) | < 0.001* | 0.63 (0.56, 0.72) | < 0.001* |
6–12 months | 0.58 (0.53, 0.63) | < 0.001* | 0.52 (0.48, 0.56) | < 0.001* | 0.51 (0.45, 0.58) | < 0.001* |
12 months and above | 0.56 (0.51, 0.61) | < 0.001* | 0.48 (0.45, 0.52) | < 0.001* | 0.48 (0.42, 0.54) | < 0.001* |
Other CVD-related conditions (i.e., Conditions used to define CVD-related death) | 1.10 (1.00, 1.20) | 0.043* | 1.18 (1.09, 1.27) | < 0.001* | ||
At least 1 diabetes-related hospitalization | 1.30 (1.23, 1.39) | < 0.001* | 1.27 (1.20, 1.33) | < 0.001* | 1.36 (1.25, 1.49) | < 0.001* |
Adapted diabetes complications severity index | 1.10 (1.08, 1.11) | < 0.001* | 1.09 (1.07, 1.11) | < 0.001* | 1.11 (1.09, 1.13) | < 0.001* |
Recorded diagnoses (ref: no diagnosis) | ||||||
Mental disorders | 1.14 (1.05, 1.24) | 0.002* | ||||
Chronic pulmonary disease | 1.18 (1.11, 1.25) | < 0.001* | 1.27 (1.21, 1.34) | < 0.001* | 1.28 (1.18, 1.40) | < 0.001* |
Obesity | 0.81 (0.74, 0.89) | < 0.001* | 0.78 (0.68, 0.88) | < 0.001* | ||
Cancer | 1.16 (1.05, 1.29) | 0.005* | ||||
Peripheral vascular disorders | 1.07 (1.01, 1.13) | 0.017* | ||||
Fluid and electrolyte disorders | 1.16 (1.09, 1.24) | < 0.001* | 1.14 (1.08, 1.21) | < 0.001* | 1.15 (1.05, 1.26) | 0.002* |
Deficiency anemia | 1.19 (1.10, 1.28) | < 0.001* | 1.15 (1.08, 1.23) | < 0.001* | 1.22 (1.10, 1.35) | < 0.001* |
Erectile dysfunction, organic origin | 0.60 (0.43, 0.84) | 0.003* | ||||
Coagulopathy | 1.14 (1.05, 1.24) | 0.003* | 1.17 (1.02, 1.33) | 0.024* | ||
Pulmonary circulation disorders | 1.21 (1.12, 1.30) | < 0.001* | 1.33 (1.18, 1.49) | < 0.001* | ||
Time interval (reference: 0–6 months) | ||||||
6–12 months | 0.82 (0.76, 0.89) | < 0.001* | 0.78 (0.73, 0.83) | < 0.001* | 0.89 (0.79, 0.99) | 0.030* |
12–18 months | 0.77 (0.70, 0.84) | < 0.001* | 0.74 (0.69, 0.80) | < 0.001* | 0.81 (0.72, 0.93) | 0.002* |
18–24 months | 0.80 (0.72, 0.89) | < 0.001* | 0.70 (0.64, 0.77) | < 0.001* | 0.82 (0.71, 0.95) | 0.009* |
24–30 months | 0.71 (0.62, 0.80) | < 0.001* | 0.58 (0.52, 0.66) | < 0.001* | 0.78 (0.65, 0.92) | 0.004* |
30–36 months | 0.67 (0.58, 0.78) | < 0.001* | 0.57 (0.50, 0.66) | < 0.001* | 0.79 (0.65, 0.96) | 0.019* |
36–42 months | 0.71 (0.59, 0.84) | < 0.001* | 0.63 (0.54, 0.74) | < 0.001* | 0.73 (0.58, 0.93) | 0.009* |
42–48 months | 0.77 (0.63, 0.93) | 0.007* | 0.70 (0.59, 0.83) | < 0.001* | 0.77 (0.59, 1.00) | 0.052 |
48–54 months | 0.61 (0.47, 0.78) | < 0.001* | 0.50 (0.39, 0.63) | < 0.001* | 0.66 (0.48, 0.90) | 0.010* |
54–60 months | 0.69 (0.53, 0.91) | 0.007* | 0.63 (0.49, 0.81) | < 0.001* | 0.75 (0.53, 1.05) | 0.097 |
Over 60 months | 0.56 (0.46, 0.69) | < 0.001* | 0.50 (0.41, 0.61) | < 0.001* | 0.51 (0.38, 0.67) | < 0.001* |